Xenetic Biosciences, Inc. (XBIO) Key Metrics
XBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.7M
- Enterprise value
- −$613,814
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.4 10-yr median 2.4
- Price / book
- 1.0 10-yr median 0.6
- EV / EBITDA
- 1.0
- Dividend yield
- —
- Beta
- 2.20
XBIO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsXBIO valuation Price multiples at each fiscal year-end price.
Price / sales−49.6%
1.2
2025 · hover or tap a bar for each year
20162025
Price / book−51.2%
0.5
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−16.1 pts
−61.9%
2025 · hover or tap a bar for each year
20162025
XBIO returns How much profit the business earns on the capital it uses.
Return on equity+10.1 pts
−40.0%
2025 · hover or tap a bar for each year
20162025
Return on assets+10.1 pts
−35.1%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+35.9 pts
−76.8%
2025 · hover or tap a bar for each year
20162025
Asset turnover+36.5%
0.39
2025 · hover or tap a bar for each year
20162025
XBIO per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+7.8%
$1.75
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$1.58
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.34
2025 · hover or tap a bar for each year
20162025
Book value per share+11.5%
$4.35
2025 · hover or tap a bar for each year
20162025
Shares outstanding+10.4%
1.7M
2025 · hover or tap a bar for each year
20162025
XBIO financial health Debt, liquidity and how easily interest is covered.
Net debt−$1.7M
−$7.9M
2025 · hover or tap a bar for each year
20162025
Current ratio+12.9%
8.32
2025 · hover or tap a bar for each year
20162025
XBIO efficiency & capital use Working capital cycle and where the cash goes.
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
XBIO valuation history
Fiscal year-endToday10-year median
XBIO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
XBIO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
XBIO cash returned to shareholders
DividendsBuybacksFree cash flow
XBIO price vs earnings per share
Share price at year-endEPS (right axis)
XBIO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.7M | $6.1M | $5.3M | $4.1M | $13.3M | $13.0M | — | — | — | — |
| Enterprise value | −$4.2M | −$15,625 | −$3.7M | −$9.0M | −$5.0M | $1.6M | — | — | — | — |
| Price / sales | 1.2 | 2.5 | 2.1 | 2.4 | 11.4 | 29.8 | — | — | — | — |
| Price / book | 0.5 | 1.0 | 0.5 | 0.3 | 0.7 | 1.1 | — | — | — | — |
| EV / sales | -1.4 | -0.0 | -1.5 | -5.3 | -4.3 | 3.6 | — | — | — | — |
| Earnings yield | −72.6% | −64.4% | −78.4% | −161.6% | −42.6% | −83.5% | — | — | — | — |
| Free cash flow yield | −61.9% | −45.8% | −78.0% | −126.9% | −35.7% | −32.7% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $2.17 | $3.99 | $3.45 | $2.85 | $12.90 | $20.40 | $14.40 | $196.80 | $230.22 | $516.00 |
| Per share | ||||||||||
| Revenue per share | $1.75 | $1.62 | $1.66 | $1.20 | $1.13 | $0.68 | — | — | — | — |
| Earnings per share | −$1.58 | −$2.57 | −$2.71 | −$4.61 | −$5.49 | −$17.04 | — | — | — | — |
| Operating cash flow per share | −$1.34 | −$1.83 | −$2.69 | −$3.27 | −$4.61 | −$6.68 | — | — | — | — |
| Free cash flow per share | −$1.34 | −$1.83 | −$2.69 | −$3.62 | −$4.61 | −$6.68 | — | — | — | — |
| Cash per share | $4.63 | $4.00 | $5.88 | $9.21 | $17.75 | $18.03 | — | — | — | — |
| Book value per share | $4.35 | $3.90 | $6.41 | $9.59 | $17.89 | $19.11 | — | — | — | — |
| Tangible book value per share | $4.35 | $3.90 | $6.41 | $9.59 | $17.89 | $19.11 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | — | — | — | — |
| Debt per share | — | — | — | — | $0.03 | $0.10 | — | — | — | — |
| Shares outstanding | 1.7M | 1.5M | 1.5M | 1.4M | 1.0M | 639K | — | — | — | — |
| Change in shares outstanding | +10.4% | +0.9% | +7.4% | +38.4% | +60.8% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −40.0% | −50.1% | −35.3% | −40.9% | −36.9% | −74.0% | −94.2% | −60.3% | −23.6% | −475.9% |
| Return on invested capital (ROIC) | — | — | −523.7% | — | −978.7% | −289.2% | −125.6% | −63.5% | −27.0% | −394.6% |
| Return on assets (ROA) | −35.1% | −45.2% | −32.7% | −37.9% | −34.2% | −62.7% | −71.0% | −43.5% | −17.9% | −286.2% |
| Return on tangible assets | −32.1% | −57.4% | −39.0% | −44.5% | −28.5% | −82.7% | −417.4% | −383.3% | −54.2% | −641.7% |
| Free cash flow margin | −76.8% | −112.7% | −162.0% | −301.5% | −408.2% | −976.6% | — | — | 19.6% | −293.5% |
| Financial health | ||||||||||
| Total debt | — | — | — | — | $27,043 | $62,525 | $20,042 | — | — | — |
| Cash & short-term investments | $7.9M | $6.2M | $9.0M | $13.1M | $18.2M | $11.5M | $10.4M | $571,605 | $5.5M | $4.0M |
| Net debt | −$7.9M | −$6.2M | −$9.0M | −$13.1M | −$18.2M | −$11.5M | −$10.3M | −$571,605 | −$5.5M | −$4.0M |
| Debt / equity | — | — | — | — | 0.00 | 0.01 | 0.00 | — | — | — |
| Debt / assets | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
| Current ratio | 8.32 | 7.37 | 11.84 | 12.72 | 13.18 | 13.20 | 7.84 | 0.75 | 3.03 | 4.47 |
| Quick ratio | 8.32 | 7.37 | 11.84 | 12.72 | 13.18 | 13.20 | 7.84 | 0.75 | 3.03 | 4.47 |
| Interest coverage | — | — | — | -40.6 | -56.6 | -0.8 | -115.3 | -301.5 | — | -65.0 |
| Working capital | $7.1M | $5.7M | $8.8M | $12.6M | $17.3M | $11.4M | $9.7M | −$405,817 | $3.9M | $6.5M |
| Invested capital | −$487,810 | −$158,388 | $812,595 | $549,869 | $177,270 | $750,497 | $6.9M | $9.3M | $8.8M | $12.1M |
| Tangible asset value | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M | $12.2M | −$1.3M | −$2.6M | $1.8M | $3.6M |
| Net current asset value | $7.1M | $5.7M | $8.8M | $12.6M | $17.3M | $11.4M | $6.8M | −$3.3M | $1.0M | $3.5M |
| Graham net-net per share | $4.06 | $3.42 | $5.35 | $8.45 | $16.37 | $17.11 | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | — | $39.5M |
| Share buybacks (net) | — | — | — | $0 | — | $0 | $0 | $0 | — | $0 |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 29.3% | 0.0% | 0.0% | 0.0% | — | 0.1% | 0.6% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | 0.6% | — |
| Capex / depreciation | — | 0.00 | — | 18.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.39 | 0.46 |
| Stock-based compensation / revenue | 2.2% | 6.9% | 11.1% | 30.0% | 35.4% | 107.3% | 5,001.3% | — | 25.3% | 70.1% |
| R&D / revenue | 103.0% | 131.5% | 137.6% | 279.5% | 272.6% | 396.3% | 28,649.6% | — | 53.5% | 1,457.9% |
| SG&A / revenue | 92.2% | 136.6% | 140.2% | 214.1% | 322.6% | 778.2% | 27,722.8% | — | 91.5% | 223.1% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 417.7 | — | — | — | 365.0 |
| Days of inventory on hand | — | — | — | — | — | — | — | — | — | 0.0 |
| Days payables outstanding | — | — | — | 4,385.4 | 3,548.3 | — | — | 19,843.9 | 2,096.8 | 13,996.7 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | — | -13,631.7 |
| Receivables turnover | — | — | — | — | — | 0.87 | — | — | — | 1.00 |
| Payables turnover | 0.00 | 0.00 | 0.00 | 0.08 | 0.10 | 0.00 | 0.00 | 0.02 | 0.17 | 0.03 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 36,449.00 |
| Asset turnover | 0.39 | 0.29 | 0.20 | 0.10 | 0.07 | 0.03 | 0.00 | 0.00 | 0.38 | 0.16 |
| Average receivables | — | — | — | — | — | $500,000 | — | — | — | $3.0M |
| Average payables | $270,862 | $262,224 | $264,096 | $324,915 | $344,933 | $629,262 | $932,638 | $860,463 | $896,841 | $1.4M |
| Average inventory | — | — | — | — | — | — | — | — | — | $1 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 85.8% | 86.8% | 65.4% | 59.7% |
Computed from XBIO's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
XBIO valuation and financial ratios
Xenetic Biosciences earned a return on equity of −40.0% in fiscal 2025.
See the XBIO income statement, the XBIO chart for price history, or the XBIO stock overview for the latest quote and news.
XBIO key metrics FAQ
What is Xenetic Biosciences's return on equity?
Xenetic Biosciences's return on equity (ROE) was −40.0% in fiscal 2025: net income of -$2.7 million on average shareholders' equity of $6.7 million.
What is Xenetic Biosciences's free cash flow yield?
Xenetic Biosciences generated -$2.3 million of free cash flow in fiscal 2025, a free cash flow yield of −61.9% on its market value at year-end ($3.7 million).
What is Xenetic Biosciences's current ratio?
Xenetic Biosciences's current ratio was 8.32 at the end of fiscal 2025: current assets were 8.32 times current liabilities.